Current Edition

announces

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors Bavarian Nordic A/S (OMX: BAVA, …

Continue Reading →